HESI RN
Reproductive System Exam Quizlet
1. Which group of the population does the Maternal nutrition component of IRH improve?
- A. Women and adolescent girls
- B. Pregnant women alone
- C. Pregnant women and all children under five
- D. All adolescents
Correct answer: A
Rationale: The correct answer is A: Women and adolescent girls. Maternal nutrition programs typically target women of reproductive age and adolescent girls to improve their health outcomes. Option B is incorrect because maternal nutrition initiatives extend beyond just pregnant women. Option C is incorrect because the focus is not on all children under five but specifically on women and adolescent girls. Option D is incorrect because the program does not target all adolescents, but rather women and adolescent girls.
2. What is one of the major issues affecting adolescents in terms of sexual and reproductive health?
- A. Limited access to contraceptives and family planning
- B. Equal representation in decision-making
- C. Decreased need for sexual education
- D. Equal opportunities for career growth
Correct answer: A
Rationale: Limited access to contraceptives and family planning is indeed a major issue affecting adolescents in terms of sexual and reproductive health. This lack of access can lead to unintended pregnancies, sexually transmitted infections, and limited reproductive choices. Choice B, equal representation in decision-making, although important, is not directly related to sexual and reproductive health issues faced by adolescents. Choice C, decreased need for sexual education, is incorrect as proper sexual education is crucial in promoting healthy behaviors and preventing risks. Choice D, equal opportunities for career growth, is also unrelated to the specific issues surrounding sexual and reproductive health in adolescents.
3. The Gravindex test is used to detect Human Chorionic Gonadotrophic hormone (HCG) in:
- A. Urine or whole blood
- B. Amniotic fluid
- C. Saliva
- D. Cervical mucus
Correct answer: A
Rationale: The correct answer is A: Urine or whole blood. The Gravindex test is designed to detect Human Chorionic Gonadotrophic hormone (HCG) in urine or whole blood samples. HCG is a hormone produced during pregnancy, and its presence in urine or blood can indicate pregnancy. Choices B, C, and D are incorrect as the Gravindex test is not intended to detect HCG in amniotic fluid, saliva, or cervical mucus. These bodily fluids are not typically used for pregnancy testing purposes.
4. Which of the following is the most effective method of contraception?
- A. Barrier methods
- B. Hormonal pills
- C. Intrauterine devices (IUDs)
- D. Sterilization
Correct answer: D
Rationale: Sterilization is considered the most effective method of contraception because it permanently prevents pregnancy. Barrier methods, hormonal pills, and IUDs are highly effective as well, but they are reversible methods and may have a higher failure rate compared to sterilization.
5. The endometrium is shed up to the basal layer during this phase of the menstrual cycle:
- A. Ovulation
- B. Regenerative
- C. Secretory
- D. Menstruation
Correct answer: D
Rationale: The correct answer is D. During the menstrual phase of the menstrual cycle, the endometrium is shed up to the basal layer. This shedding occurs as a result of decreased levels of estrogen and progesterone, leading to the breakdown and subsequent shedding of the endometrial lining. Choice A, ovulation, is incorrect as ovulation is the release of an egg from the ovary, which occurs during the mid-cycle. Choice B, regenerative, is incorrect as it does not specifically refer to the phase where the shedding of the endometrium occurs. Choice C, secretory, is incorrect as it refers to the phase where the endometrium thickens in preparation for possible implantation of a fertilized egg, not shedding.
Similar Questions
Access More Features
HESI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All HESI courses Coverage
- 30 days access
HESI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All HESI courses Coverage
- 30 days access